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After a safety review of hydroxyethyl starch (HES) solutions in 2013, restrictions on the
use of HES were introduced in the European Union (EU) to reduce the risk of kidney injury
and death in certain patient populations. Similar restrictions were introduced by the Food
and Drug Administration in the United States and other countries. In October 2017, a
second safety review of HES solutions was triggered by the European pharmacovigilance
authorities based on a request by the Swedish Medical Products Agency to completely
suspend HES. After several meetings and repeated evaluations, the recommendation
to ban HES was ultimately not endorsed by the responsible committee; however, there
was a vote for more restricted access to the drug and rigorous monitoring of policy
adherence. This review delineates developments in the European pharmacovigilance risk
assessment of HES solutions between 2013 and 2018. In addition, the divergent experts’
opinions and the controversy surrounding this official assessment are described. As the
new decisions might influence the availability of HES products for veterinary patients,
potential alternatives to HES solutions, such as albumin solutions and gelatin, are briefly
discussed.
Keywords: gelatin, dextran, plasma expanders, pharmacovigilance, synthetic colloids, fluid therapy, European
Medicines Agency, Food and Drug Administration
First introduced in the 1960s, hydroxyethyl starch (HES) rapidly became the most commonly
used synthetic colloid in human intensive care units (ICUs) throughout the world, with over 60
products registered in Europe and four in the United States (US) by the year 2010 (1–3). The first
veterinary reviews advocating the use of HES date from the 1980s and, until recently, veterinarians
have been widely using these products to treat anesthesia-induced hypotension and hypovolemia
non-responsive to crystalloids (4, 5). Additionally, HES has been used to increase intravascular
colloid osmotic pressure in hypoalbuminemic animals by administering it as a low-dose constant
rate infusion over several days (6–8). However, an increasing number of potential side effects of
HES administration in both humans and animals have since come to light. These include tissue
accumulation, acute kidney injury (AKI), coagulopathies and bleeding tendencies, anaphylactoid
reactions, and pruritus (the latter only described in humans) (9–11). The nephrotoxic effects of
HES have been proposed to be secondary to renal tissue uptake and intracellular storage based
on studies in small populations of patients (12, 13). As HES molecules cannot be degraded once
they leave the blood, HES leads to vacuolization, swelling, and subsequent cellular dysfunction in
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the kidney (12, 13). HES-induced coagulopathies and bleeding
are suggested to be the result of direct effects on hemostasis
through impaired fibrinogen/fibrin polymerization and platelet
dysfunction leading to a weaker clot (14, 15).
Awareness of these side effects has resulted in a succession of
changes to the warnings, restrictions, and contraindications on
HES product packaging (Table 2) and prompted lively debates
in the intensive care community about the potential risks and
theoretical benefits of HES administration. This review traces
back the history and summarizes the current state of regulations
on HES use in human medicine. Its purpose is to inform
the reader on the origins of the controversy surrounding HES
use. Furthermore, a brief overview on HES-related veterinary
literature as well as alternatives to HES is presented to help the
reader understand the impact (or lack thereof) of the potential
loss of access to HES for veterinary patients.
THE HISTORY OF HES
RESTRICTIONS—FIRST EPISODE 2013
In 2008, the Efficacy of Volume Substitution and Insulin Therapy
in Severe Sepsis (VISEP) trial, a multicenter human randomized
controlled trial (RCT) conducted in 537 septic patients in
Germany, found higher rates of AKI and need for renal-
replacement therapy (RRT) associated with the use of 10% HES
200/0.5 than with Ringer’s lactate (16). In this study, a number
of patients received higher than recommended dosages of the
hyperoncotic HES 200/0.5 (>22 ml/kg per day); however, the
increased risk to need RRT was also seen in patients treated with
HES 200/0.5 at the recommended daily doses (16). This trial
was followed by three other large human multicenter RCTs in
critically ill or septic patients in 2012 (17–19). The Scandinavian
Starch for Severe Sepsis/Septic Shock (6S trial) involving 798
septic patients, found an increased requirement for RRT and
higher mortality at 90 days in patients receiving 6% HES
130/0.42 compared to Ringer’s acetate (17). The Crystalloid vs.
Hydroxyethyl Starch Trial (CHEST trial) involving 7,000 critically
ill patients in Australia and New Zealand, also found a higher
requirement for RRT but no difference in 90-day mortality in
patients receiving 6% HES 130/0.4 compared to saline (18).
Finally, the Assessment of Hemodynamic Efficacy and Safety of
6% Hydroxyethylstarch 130/0.4 vs. 0.9% NaCl Fluid Replacement
in Patients with Severe Sepsis (Crystalloids Morbidity Associated
with severe Sepsis, CRYSTMAS) trial involving 196 septic
patients in France and Germany, found no difference in adverse
events, including AKI and mortality, between patients receiving
6% HES 130/0.4 compared to saline (19).
Abbreviations: 6S, Scandinavian Starch for Severe Sepsis/Septic Shock; AKI,
acute kidney injury; CHEST, Crystalloid vs. Hydroxyethyl Starch Trial;
CHRYSTMAS, Crystalloids Morbidity Associated with severe Sepsis; CMDh,
Coordination Group for Mutual Recognition and Decentralized Procedures—
Human; EMA, European Medicines Agency; EU, European Union; FDA,
Food and Drug Administration; HES, hydroxyethyl starch; ICU, intensive care
unit; MAH, marketing authorization holders; NGAL, neutrophil gelatinase-
associated lipocalin; PRAC, Pharmacovigilance Risk Assessment Committee; RCT,
randomized clinical trial; RRT, renal-replacement therapy; US, United States;
VISEP, Volume Substitution and Insulin Therapy in Severe Sepsis.
Simultaneously with the aforementioned trials, between 2009
and 2013, one of the largest scandals of scientific misconduct in
history was unraveled (20, 21). This involved retractions of over
90 HES-related scientific articles of the (back then) prominent
German anesthetist and prolific defender of HES, Joachim Boldt,
for data fabrication and lack of ethics approval (22, 23). Data
from studies by Boldt and coworkers were included in systematic
reviews and used to form clinical guidelines worldwide (24,
25). In particular, re-evaluation of one meta-analysis that
originally reported no association between HES administration
and all-cause mortality, revealed a significantly increased risk of
mortality and AKI when 7 studies from Boldt were subsequently
excluded from the analysis (26). This elucidates the fact that
the fraudulent data from Boldt’s many years of research, which
mostly favored HES, might have previously tipped the “meta-
analytical scales” andmasked the potential harm of HES products
for many years (21).
Following, VISEP (16), 6S (17), CHEST (18), and CRYSTMAS
(19), both the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) initiated a safety review of
HES products. Both agencies reviewed data from RCTs, meta-
analyses and observational studies, with a particular emphasis
on 6S (17) (FDA and EMA), CRYSTMAS (19) (FDA only),
and CHEST (18) and VISEP (16) (EMA only) (3). The EMA
review was started in November 2012 by the Pharmacovigilance
Risk Assessment Committee (PRAC) as a referral procedure
(Article 31 of Directive 2001/83/EC) and was initiated at the
request of the German medicines agency (Data Sheet 1) (27, 28)
(Table 1). The PRAC is a section of the EMA composed of
experts from each of the member states of the EU as well as
members representing patient organizations responsible for all
aspects of risk management of medicines (43). In June 2013,
the PRAC issued a recommendation to suspend marketing
authorization for all HES products as it concluded that the risks
of HES outweighed its benefits (29) (Table 1). In the interim,
HES was banned by the British Medicines and Healthcare
Products Regulatory Agency, and a drug alert was issued in the
United Kingdom calling for the return of all HES products to
the manufacturers (44). Simultaneously, the United Kingdom
triggered an urgent Union procedure (Article 107i of Directive
2001/83/EC) which was performed by PRAC as well (31).
Such procedure is automatically triggered when a member state
considers suspending marketing authorization or prohibiting
supply of a medical product (45) (Table 1).
Numerous commentaries in scientific journals were
exchanged between experts with different opinions regarding the
risks and benefits of HES, and the quality of the aforementioned
landmark trials. Concerns raised by HES proponents (and
Marketing Authorization Holders [MAHs]) with regard to the
VISEP (16), 6S (17), and CHEST (18) trials included that patients
were entered into studies several hours after admission to ICU
(up to 24 h after) and were possibly hemodynamically stable at
randomization, wherefore HES was no longer indicated. Also, a
significant number of patients who were randomized to receive
HES were in renal failure. Namely, renal failure without RRT
was not an absolute contraindication for HES according to
the steering committee and scientific advisors of the 6S (17)
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TABLE 1 | Timeline for regulatory key events in 2013 and 2018 for hydroxyethyl starch (HES) restrictions by the European Medicines Agency’s (EMA) Pharmacovigilance
Risk Assessment Committee (PRAC).
Date Event
30th November 2012 Review of HES solutions started under Article 31 of Directive 2001/83/EC (28).
14th June 2013 PRAC recommends suspending marketing authorizations for infusion solutions containing HES (29).
12th July 2013 Recommendation to suspend marketing authorizations for HES solutions to be re-examined under Article 31 of Directive 2001/83/EC (30).
12th July 2013 New review of HES-containing solutions for infusion started under Article 107i of Directive 2001/83/EC (urgent Union procedure triggered by
the United Kingdom) (31).
11th October 2013 PRAC confirms that HES should no longer be used in patients with sepsis or burn injuries or in critically ill patients. HES will be available in
restricted patient populations (32).
25th October 2013 CMDh endorses PRAC recommendations: HES solutions should no longer be used in patients with sepsis or burn injuries or in critically ill
patients (33)
6th March 2014 European Commission final decision: HES solutions no longer to be used in patients with sepsis or burn injuries or in critically ill patients (34)
27th October 2017 EMA starts new review of HES containing medicines at the request of the Swedish Medical Products Agency, under Article 107i of Directive
2001/83/EC (35).
12th January 2018 PRAC recommends suspending HES solutions for infusion from the market (36).
26th January 2018 HES solutions for infusion to be suspended—CMDh endorses PRAC recommendation (37).
9th April 2018 European Commission/ Meeting of the Standing Committee On Medical Products For Human Use refers back the CMDh position/PRAC
recommendation to the European Medicines Agency for further consideration (38).
17th May 2018 PRAC confirms its recommendation to suspend HES solutions for infusion in the EU (39, 40).
29th June 2018 HES solutions: CMDh introduces new measures to protect patients (41).
27th July 2018 European Commission final decision: Scientific conclusions and CMDh’s detailed explanation on the scientific grounds for differences with the
PRAC recommendation (42).
CMDh, Coordination Group for Mutual Recognition and Decentralized Procedures—Human.
trial, despite that renal failure was already a contraindication
for HES [stated e.g., by the American FDA (46)] before 6S was
initiated (47). Some patients randomized to the crystalloid group
had received initial treatment with colloids, and there was a
lack of specific criteria for starting RRT. Finally, there was no
justification for extrapolating findings in critically ill patients to
the entire patient population (47–50). HES opponents disagreed
with these critiques against VISEP (16), 6S (17), and CHEST (18)
and argued that data were misread and misinterpreted by the
critics (51).
In March 2013, another large human RCT was published: The
Colloids vs. Crystalloids for the Resuscitation of the Critically Ill
(CRISTAL) trial randomized 2,857 critically ill patients in 57
ICUs in France, Belgium, North Africa, and Canada, requiring
fluid resuscitation for acute hypovolemia with either colloids
(gelatins, dextrans, HES, or albumin) or crystalloids (isotonic
saline, hypertonic saline, or any other buffered solution) (52).
Even though the trial was open-label, the outcome assessment
was blinded, and patients received HES within the maximum
dose limit. The study found no significant difference in the 28-day
mortality between subjects receiving colloids and those receiving
crystalloids, but a significant reduction in mortality at 90 days
in the colloid group, as well as more vasopressor-free and more
ventilator-free days by day 28 (52). Subgroup analysis confirmed
a significantly reduced 90-day mortality in patients treated with
HES when compared with patients treated with 0.9% saline. In
contrast to VISEP (16), 6S (17), and CHEST (18) the authors
of CRISTAL (52) recruited patients newly admitted to the ICU
as soon as resuscitation was required. Nevertheless, the trial had
limitations, such as long duration of the trial (9 years), open-label
design, only 70% of patients in the colloid group received HES,
overlap between treatments with the different colloids, some
patients received more than one type of colloid, and a high
proportion of patients in both groups received colloids prior to
ICU colloid administration (52).
Following requests for re-examination by MAHs, including
Fresenius Kabi and B. Braun Melsungen AG (located in
Germany), a second PRAC committee, composed of a different
expert group, re-evaluated the evidence (30) (Table 1). The re-
examination focused on the benefit-risk ratio of HES in the
treatment of hypovolemic shock in surgery and trauma patients
(53). Consequently, two reviews were running in parallel by
different expert committees of the PRAC: The re-examination
under Article 31 of Directive 2001/83/EC [requested by the
MAHs) (30)] and the additional review under Article 107i of
Directive 2001/83/EC [triggered by the United Kingdom in
June 2013 (31)]. Both reviews were finalized in October 2013
but came to different conclusions. The PRAC review under
Article 31 maintained its recommendation (from June 2013) for
suspension of marketing authorization for HES (53). However,
a re-examination only looks at the evidence provided for the
original procedure and therefore, this committee did not include
new data (53). In contrast, the PRAC review under Article 107i
included new data, which were not available or not considered in
the referral under Article 31 and did not recommend an absolute
HES suspension (54). Factors that led to a different assessment
of that review were short-term hemodynamic improvement (55),
volume-sparing effect (56), prevention and limitation of edema
formation (57), significantly lower estimated blood loss (58), and
reduction in red blood cell transfusions (59) in surgical and
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TABLE 2 | Contraindications for hydroxyethyl starch products before and after
2013 in the European Union (EMA) and United States (FDA).
EMA FDA
Contraindications before 2013
Renal failure (with oliguria or anuria)
Patients on dialysis
Hypersensitivity
Congestive heart failure
Hyperhydration states (including
pulmonary edema)
Intracranial bleeding
Severely impaired hepatic function
Hyperkalemia
Severe hypernatremia or hyperchloremia
Clinical conditions with volume overload
Contraindications before 2013
Renal failure (with oliguria or anuria)
Hypersensitivity
Congestive heart failure
Treatment of lactic acidosis
Patients on dialysis
Clinical conditions with volume overload
Additional contraindications in 2013
Critically ill patients
Sepsis
Burn injuries
Renal impairment
Renal replacement therapy
Severe coagulopathy and bleeding
Organ transplant patients
Additional contraindications in 2013
Critically ill adult patients
Sepsis
Renal dysfunction
Severe liver disease
Pre-existing coagulation/bleeding
disorders
Patients undergoing open heart surgery
in association with cardiopulmonary
bypass
Additional contraindications in 2018
Fluid maintenance therapy
Dehydrated patients
Cerebral hemorrhage
No update
EMA, European Medicines Agency; FDA, United States Food and Drug Administration.
trauma patients receiving HES (54). Further, studies provided
some evidence that the risks of AKI (60, 61) and death (52, 62)
in these patients may be lower than in critically ill and septic
patients (54). The PRAC’s final recommendation on the use of
HES solutions was based on the new evidence considered in
the Article 107i procedure and the decision was published in
October 2013 on the EMA website (32) (Table 1). Notably, in
the online regulatory texts provided by the EMA, no difference
is made regarding different HES preparations (e.g., second
generation HES 200/0.5 vs. third generation HES 130/0.4 or
0.42, respectively). The EMA recommended that HES should
no longer be used in critically ill patients or those with sepsis
or burn injuries (Table 2), but it could still be administered to
patients with hypovolemia due to acute blood loss if treatment
with crystalloids was inadequate. In these patients, HES should
be only given for initial volume resuscitation with a maximum
dose of 30 ml/kg and kidney function should be monitored for
90 days (although the type of monitoring was not specified)
(32). Only Annex III “Amendments to relevant sections of
the summary of product characteristics and package leaflet”
specifically mentioned the HES preparations (HES 130/0.4 and
HES 130/0.42, respectively) and stated that for other HES
products (e.g., HES 200/0.5) the maximum daily dose should be
recalculated accordingly (63).
This decision was not unanimously supported, as 14 of the 33
PRACmembers voted against the revision (54). Nevertheless, the
decision was endorsed by the Coordination Group for Mutual
Recognition and Decentralized Procedures—Human (CMDh,
responsible for examining questions relating to marketing
authorization of human medicines in the EU, composed of one
representative per EU Member State) (33), and then by the
European Commission, the governing body of the EU, for legal
binding in the EU (34) (Table 1). As a condition from the PRAC,
the MAHs were asked to conduct drug utilization studies in
several member states to evaluate the effectiveness of the risk
minimization measures taken. The goal of these drug utilization
studies was to characterize prescribing practices during typical
clinical use in representative groups of prescribers to verify
adherence to the updated product information. As further
conditions, changes to the product information, information to
the healthcare professionals and patients, and RCTs conducted
by the MAHs in order to demonstrate the efficacy and safety of
HES in the perioperative and trauma populations were requested
(54).
For the FDA review, an expert workshop was set up to
review HES safety (64). This led to new safety information
added to HES product labeling in November 2013 in the
form of a black box warning. It stated not to use HES in
critically ill adult patients, and patients with sepsis, severe liver
disease, pre-existing coagulopathy, and in patients undergoing
open heart surgery in association with cardiopulmonary bypass
(Data Sheet 2) (65) (Table 2).
The revised EMA decision was criticized, as it was (for the
most part) based on the same studies as the ban had been based
on, but with different conclusions (66). HES opponents argued
that the risks of HES outweighed the benefits, that there was
insufficient evidence that colloid resuscitation improved outcome
in surgical and trauma patients, and that a number of other,
safer alternative intravenous fluids existed (67, 68). In a 2014
open letter to the Executive Director of the EMA, the authors
(overall 70 intensive care researchers) asked, “what assumptions
or clinical data would indicate that the same pathological
mechanisms [tissue storage with subsequent organ injury, and
coagulopathy] do not apply in patients with hypovolemia from
blood loss” and argued that the known side effects should be
considered to be potential risks in all patient groups. Further, the
clinical trials recommended by the PRAC to prove the safety of
HES would expose surgical and trauma patients to known risks
of harm [e.g., risk of AKI and bleeding] without a proven benefit
(67). At the same time, CHEST (18) investigators were heavily
criticized by HES defenders due to changes in their methods,
statistical analysis, and data after publication in 2012 as well as
refusal to share their raw data for independent reanalysis (69, 70).
A reanalysis of the CHEST (18) trial was ultimately published
in 2016 (confirming the conclusion of the original article), but
only two of the eight authors of this reanalysis were from an
independent institution. All other listed authors came from the
institution which conducted the original study, including three
authors who were part of the original 2012 publication, one of
which was the prior study’s principal investigator (71).
Based on the 2013 PRAC recommendation for the MAHs to
conduct human RCTs, Fresenius Kabi and B. Braun Melsungen
AG, together with the European Society of Anesthesiology,
launched two RCTs in 2017 (72, 73). The Safety and Efficacy of
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a 6% Hydroxyethyl Starch Solution vs. an Electrolyte Solution in
Trauma Patients (TETHYS) trial will include up to 350 patients
with blunt or penetrating trauma suffering from an estimated
blood loss of ≥ 500ml and subsequent hypovolemia, who are
undergoing surgery within 24 h. The primary endpoint is 90-
day mortality and 90-day renal failure (defined as biomarker
increase as defined by AKIN stage 2 or RIFLE injury stage or
need for RRT at any time during the first 3 months) (73). The
Safety and Efficacy of 6% Hydroxyethyl Starch Solution vs. an
Electrolyte Solution in Patients Undergoing Elective Abdominal
Surgery (PHOENICS) trial will include up to 2,280 patients
undergoing elective abdominal surgery with an expected blood
loss of ≥ 500ml and subsequent hypovolemia. Primary outcome
is the difference in glomerular filtration rate between the two
treatment groups (72).
The regulatory changes and controversy regarding HES led
to a worldwide decrease in synthetic colloid use in human ICUs
between 2007 and 2014, with considerable geographic variations
and an increase in the use of human albumin instead (74).
THE HISTORY OF HES
RESTRICTIONS—SECOND EPISODE 2018
In February 2017, the US-based Public Citizen Foundation sent
a petition to the FDA requesting the immediate removal of all
HES products from the market in the US (75). The FDA has yet
to undertake official action. The Public Citizen Foundation also
joined other experts in signing an open letter to the EMA urging
the executive director to reconsider the 2013 PRAC decision
and ban the use of HES products for all patients in Europe
(Data Sheet 4) (76). In addition, in October 2017, the Swedish
Medical Products Agency requested a review of HES products
and considered its suspension due to concerns regarding non-
compliance to restrictions in their use (Data Sheet 3) (77). Two
survey-based drug utilization studies conducted in 2016 and
2017, involving 11 European countries, showed non-adherence
to the 2013 PRAC restrictions of up to 77% (77). They showed
that HES solutions have continued to be used in high-risk
populations (up to 34% of patients) (Data Sheet 5) (78, 79).
In October 2017, the EMA started a new review of HES
under Article 107i of Directive 2001/83/EC (35) (Table 1).
Upon request from the PRAC, the EMA convened an ad-
hoc expert group meeting in December 2017 [minutes of this
meeting are not publicly available (80)]. In January 2018, the
PRAC recommended removing all HES products from the
European market (36) (Table 1). The recommendation was
endorsed by the CMDh (37) and forwarded to the European
Commission (Table 1). Several experts worldwide supported this
decision by publishing open letters and comments in scientific
journals (81, 82). A group of British, Australian, Danish, and
German scientists [some of them 6S (17) or CHEST (18) trial
investigators] even appealed to the World Health Organization
(WHO), demanding a worldwide ban of HES (82). In contrast, a
group of European scientists [some of them CRISTAL (52) trial
investigators] responded that the recommendation to suspend
HESwas “not scientifically grounded and is potentially hazardous
to patients” (83). In addition, experts who were part of the EMA
ad-hoc expert group from December 2017 complained that part
of their recommendation not to suspend HES was left out in the
official PRAC recommendation on the EMA website (80, 84).
Criticism regarding the PRAC recommendation also came from
a group of 19 European anesthesia societies in the form of an
open letter to the European Commission (85). In this letter, they
urged the European Commission to denounce the suspension
of HES products. They criticized the validity of the survey-
based drug utilization studies that showed non-compliance of
PRAC recommendations, because respondents could only select
dehydration or overhydration as a reason for administering HES
(no check box for hypovolemia was provided). Moreover, it was
unclear as to whether or not some septic patients had received
HES before the development of sepsis. It was also criticized that
suspension of HESwould lead to unmet clinical needs for colloids
in specific situations, such as plasmapheresis, pediatric cardiac
surgery, and prevention of hypotension in patients undergoing
cesarean section with spinal anesthesia. They claimed that if HES
were to be suspended, there would be no alternative colloid, as
dextran, gelatin, or albumin are not superior to HES. Finally,
the experts also strongly recommended that HES should not
be suspended before the results of the PHOENICS (72) and
TETHYS (73) trials become available (84). Not surprisingly,
European HES solution manufacturers also claimed that HES
should remain available on the market, stating that the off-
label use of a product by clinicians is not a sufficient argument
to withdraw it from the market (86, 87). Accordingly, the
new PRAC recommendation and CMDh position were referred
back to the EMA by the European Commission in April 2018,
as the concern regarding unmet medical needs (e.g., no safe
alternative to HES solutions) and the feasibility and effectiveness
of risk minimization measures (e.g., changes to the product
information, direct health care professional communication) had
not been adequately addressed (38) (Table 1).
In May 2018, after re-assessing data on these specific aspects,
the PRAC confirmed its previous recommendation that HES
solutions should be suspended and sent it again to the CMDh
for consideration (39) (Table 1). For the re-assessment, the PRAC
reviewed “all newly available data since the previous referral
procedures, including results from drug utilization studies,
clinical studies, meta-analyses of clinical studies, post-marketing
experience, EudraVigilance data (adverse reactions reporting
system), literature reviews, responses submitted by MAHs as well
as stakeholders’ submissions (e.g., different European anesthesia
societies), and views expressed by experts during an ad-hoc
experts meeting” (40). In regard to the efficacy of HES, the
PRAC concluded that although a volume-sparing effect in
patients undergoing surgery was demonstrated in some studies,
it remained uncertain to what extent this leads to improved
postoperative outcomes (88–90). In regard to safety in septic,
critically ill, and surgical patients, the quality of new studies were
deemed to be insufficient to change the existing restriction (40).
In fact, since 2013, some post-hoc analyses of the 6S (17) trial
have been published, evaluating AKI in the first 5 days (results
in favor of crystalloids) (91), the risk of bleeding and death
(results in favor of crystalloids) (92), cytokine concentrations
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(results reveal no difference between crystalloids and HES) (93),
and endothelial damage (results in favor of HES) (94). However,
there have been no large RCTs performed, comparable with the
previous landmark trials VISEP (16), 6S (17), and CHEST (18).
In summary, the PRAC concluded that the volume-sparing effect
of HES in patients with hypovolemia is only modest, the key
results of the two drug utilization studies were reliable, and that
non-adherence to the revised product information was high.
Accordingly, the PRAC stated that the benefits of HES solutions
did not outweigh the risks, its continued use raised important
public health concerns, and current risk minimization measures
(e.g., information on the package insert) were inadequate (40).
This time, the CMDh disagreed with the conclusions of the
PRAC and decided that HES products should not be withdrawn
from the market in June 2018 (41) (Table 1). The rationale for
this dissenting decision was the potential unmet medical needs
in some of the EU member states, in which HES alternatives
may be of limited availability or very expensive. In addition,
measures to minimize risk were to be implemented, including
contraindications (Table 2), limitations on supply to accredited
hospitals, training of healthcare professionals, and additional
packaging warnings (42). Like the 2013 sanctions, the PRAC
recommended that HES use should be limited to initial volume
resuscitation with a dose not exceeding 30 ml/kg over a period
of administration not exceeding 24 h, and that kidney function
should be monitored for at least 90 days thereafter (Data sheet 3)
(42).
At the time of writing this review and to the authors’
knowledge, no new regulations beyond the 2013/2014 restrictions
have been published from non-EU countries, such as Canada, US,
Australia, New Zealand, and Switzerland.
HYDROXYETHYL STARCH IN VETERINARY
MEDICINE
Synthetic colloids are widely used in veterinary medicine with
HES being the most frequently used according to a recent
international internet-based survey in small animals from 2016
(4) and a previous Veterinary InformationNetwork-based survey
from 2013 (95). According to the survey from 2016 (4), HES
was selected as the most frequently used synthetic colloid by
84%, gelatin by 4.3%, and dextran by 2.7% of the survey
participants. Several review articles critically highlighting the
expected effects (e.g., volume effect, increase in colloid-osmotic
pressure, plugging endothelial leaks), limitations, and side effects
of synthetic colloids, and HES in particular, were recently
published (10, 96–99). However, no official guidelines from
veterinary experts on the use of HES have thus far been provided.
The gaps in species-specific HES-related evidence in veterinary
medicine has led to extrapolation of previous indications
from human medicine with some exceptions. Notably, many
veterinarians seem to use HES as a constant rate infusion
for colloid osmotic support, which is uncommon in human
medicine (4, 8). Not surprisingly, the changes in human
recommendations impacted veterinary medicine. Reduction of
frequency, dose, and length of administration of HES products
was noted in the 2016 survey (4), with 71% of participants
having changed their use of HES due to safety concerns.
Of these, AKI and coagulopathy were most often considered
contraindications for HES (4). Participants who completely
stopped using HES, replaced it with isotonic crystalloids in
85%, plasma in 63%, hypertonic saline in 57%, albumin in
28%, and other/unspecified in 3% of respondents. About half of
these participants reported using vasopressors more frequently
(4).
The evidence regarding the risk of HES-induced AKI in dogs
and cats remains controversial. Four retrospective studies found
no increased risk of AKI after 6% HES 130/0.4 (tetrastarch)
administration in dogs and cats (100–103), and one retrospective
study found evidence for an increased risk of AKI and mortality
in dogs receiving 10% HES 200/0.5 (pentastarch) (104). Reasons
for these discrepant findings may lie in different types of
HES products used (older-generation pentastarch in the study
that found increased incidence of AKI vs. newer generation
tetrastarch in the other four studies), definitions of AKI,
co-morbidities, severity of illness scores and dose regimens.
Prospective RCTs evaluating HES-induced AKI in critically
ill and/or anesthetized dogs or cats are still lacking. Only
one recent study in a small population of dogs undergoing
emergency abdominal surgery reported increased levels of
urinary neutrophil gelatinase-associated lipocalin (NGAL) after
6% tetrastarch administration compared to the use of an isotonic
crystalloid after surgery (105). Notably, this study was not
designed to compare AKI incidence after HES vs. crystalloid use,
fluid administration was not randomized, and therefore results
should be interpreted with caution. In a prospective crossover
study in healthy, anesthetized dogs with acute controlled
hemorrhage, resuscitation with 20 ml/kg 6% tetrastarch did not
reveal evidence of AKI (assessed by urine and plasma NGAL
and creatinine) for up to 72 h after its administration (106).
Likewise, a recent abstract presented a controlled hemorrhagic
shock model in anesthetized dogs treated with a bolus of
either 6% tetrastarch, 4% succinylated gelatine, fresh whole
blood, or an isotonic crystalloid, HES did not lead to a greater
incidence of AKI (assessed by different renal biomarkers, e.g.,
urinary NGAL, and renal histopathology) compared to the other
resuscitations fluids (107). Furthermore, a 72-h infusion of 6%
tetrastarch at 50 ml/kg per 24 h did not significantly impact renal
function (assessed by urinary NGAL and renal histopathology)
in healthy dogs as shown in a recent study presented in an
abstract (108). The small study populations and the studies’
experimental nature, not representative of the typical cohort of
critically ill patients, needs to be taken in consideration before
clinical decisions can be based on these results. Furthermore,
scientific abstracts often present only partial information and
are not submitted to the full scrutiny of a peer-reviewed process
reviewing the entire dataset, methods, and limitations of the
respective study.
A fair amount of in vitro and in vivo studies evaluating
the effects of 6% tetrastarch on hemostasis exists in dogs
(8, 109–116), but only one in vitro study in cats (117).
In dogs administered 6% tetrastarch, a dose-dependent
impairment of platelet function and changes in viscoelastic
coagulation testing (rotational thromboelastometry [ROTEM]
or thromboelastography) in healthy dogs (109, 110, 113, 114),
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dogs with controlled hemorrhagic shock (112, 116), and dogs
with sepsis was found (111). However, no difference in platelet
function was found between 20 ml/kg of 6% tetrastarch and a 3-
to 4-fold volume of 0.9% NaCl in healthy dogs (in vitro) (114)
or in dogs with controlled hemorrhagic shock (in vivo) (112).
These findings suggest that 6% tetrastarch does not cause platelet
dysfunction beyond the effects of hemodilution alone. In a
similar experimental model in dogs with controlled hemorrhagic
shock, dogs received 20 ml/kg of 6% tetrastarch, 4% succinylated
gelatine, fresh whole blood, or 80 ml/kg of an isotonic crystalloid
solution. Plasmatic coagulation testing and ROTEM showed
evidence of mild hypocoagulability beyond hemodilution after
HES and gelatin administration, with gelatin administration
leading to impaired platelet function and HES administration
causing hypocoagulable ROTEM and plasma coagulation
assays (116). In dogs with naturally-occurring hemorrhagic
shock due to spontaneous hemoperitoneum receiving boluses
of either 10 ml/kg of 6% tetrastarch or 30 ml/kg of isotonic
crystalloid, an exacerbation of the pre-existing coagulopathy
was found after both solutions in plasma coagulation and
ROTEM assays, with more pronounced effects on ROTEM after
HES (118). Therefore, HES should be avoided or used with
caution in dogs at risk for hemorrhage or with pre-existing
coagulopathy.
ALTERNATIVES TO HES SOLUTIONS
The impact HES restrictions will have on veterinary practice in
Europe and elsewhere is uncertain and alternative products will
have to be considered. Potential available replacements for HES
in people [that have been said to be safer but just as effective,
as stated e.g., by a regulatory citizen petition (75)], are gelatin
solutions (Europe), dextran (US), albumin solutions, and isotonic
crystalloids. A detailed discussion of the benefits and risks of each
of these products is beyond the scope of this review. However,
significantly less evidence exists in the small animal literature
about the efficacy and safety of gelatin and dextran compared to
HES.
Gelatin solutions are derived from the degradation of bovine
collagen with subsequent chemical modifications to increase
solubility (119). Due to their smaller molecular weight compared
to HES, gelatins are rapidly excreted by the kidneys and
provide a shorter and less pronounced intravascular volume
effect (10). Similar to HES, gelatin solutions were introduced
into clinical practice in the 1960s before current information
requirements for licensing and extensive safety studies were
mandatory (119). A meta-analysis in humans concluded that
the safety and efficacy of gelatins cannot be assessed based on
available evidence despite 60 years of use (120). Gelatin solutions
increase the risk of anaphylaxis and may further be harmful by
increasing mortality through renal failure and bleeding due to
extravascular uptake and coagulation impairment, respectively
(121). In a recent prospective study in people with severe
sepsis, AKI occurred in 70% of patients receiving HES and
in 68% of patients receiving gelatin vs. 47% patients receiving
crystalloids. Moreover, in the same study, fluid resuscitation
with only crystalloids was equally effective (122). Gelatin has
been investigated much less in dogs or cats than HES. Only
a few and mostly experimental studies (not related to the risk
of AKI) on the use of gelatins in dogs and cats have been
published (123–129). In a recent abstract, a greater incidence
of kidney injury after the administration of a 4% gelatin
solution compared to the administration of 6% tetrastarch,
fresh whole blood, or an isotonic crystalloid in a controlled
hemorrhagic shock model in anesthetized dogs was reported
(107). In this study, a variety of urinary biomarkers as well
as renal histopathology were evaluated, and dogs given gelatin
had significantly increased NGAL concentrations (with up to
a 23-fold increase) within 3 h and increased cystatin C levels,
compared to other treatments. Tubular injury scores assessed
by histopathology were comparable across treatments, while
microvesiculation (intracellular storage of colloid molecules) was
significantly higher in the gelatin group (107). Notably, gelatin
was withdrawn from the US market in 1978 due to safety
concerns over increased blood viscosity and blood coagulation
(130). In other countries (e.g., Germany), it is licensed and
despite evidence of AKI after intravenous gelatin administration
in people (131), it is not labeled to be contraindicated in
kidney disease. Indeed, there is no clear dose or maximum daily
limit, and the recommendation on the package insert states
that the “maximum daily dose is determined by the degree of
hemodilution” (Data Sheet 6) (132, 133).
Dextran, a macromolecular polysaccharide, has been
withdrawn from the market in a number of European countries
(e.g., Germany) due to its adverse effects, such as anaphylactic
reactions, osmotic kidney failure with hypertonic dextran
preparations, and impaired coagulation (2). By contrast, dextran
is licensed in the US, Russia, China, some eastern European
countries, and Scandinavia (e.g., Sweden, Norway) (2). In
dogs, dextran and hypertonic dextran have been studied in
septic shock secondary to pyometra (134), hemorrhagic shock
(135, 136), and gastric dilatation volvulus (137, 138). In addition,
investigations of its effects on hemostasis are available (139, 140).
Evaluation of the effects of oxypolygelatin and dextran 70
on hemostatic variables in healthy dogs showed that both
dextran and oxypolygelatin interfered with hemostatic variables
(e.g., plasma coagulation assays, platelet numbers, factor VIII
coagulant activity, von Willebrand factor antigen concentration,
and platelet function and buccal mucosal bleeding time),
but dextran’s effect was more profound and prolonged when
compared to oxypolygelatin (140).
Canine albumin (e.g., lyophilized canine albumin)
manufactured in the US, is currently shipped only to Hong
Kong, Taiwan, Singapore, and Canada. Consequently, other
countries are forced to use human serum albumin products if
they wish to administer albumin to their canine or feline patients.
No feline albumin products are currently commercially available.
Clear evidence of anaphylactic reactions and life-threatening
complications after administration of human serum albumin
were reported in dogs (141, 142), although large retrospective
studies have not demonstrated a high complication rate with
human serum albumin solutions use in critically ill dogs and cats
(143, 144).
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CONCLUSION
Despite two PRAC expert committees (in 2013 and 2018)
recommending suspension of the use of HES and after several
reviews and intense discussions, the European Commission
decided against a total suspension of HES in July of 2018. Instead
of a suspension, additional restrictions have been implemented,
allowing its continued use as long as access is controlled and
warnings on the packaging inserts are clearly stated. Most
likely, this is not the final episode of the HES “saga” as large
human RCTs are currently ongoing. In spite of, or maybe
because of the HES-controversy, HES is currently the most
studied synthetic colloid in human and veterinary medicine.
The complicated process of these safety reviews illustrates the
difficulties in decision making regarding such a wide-spread
drug, particularly when multiple countries with different claims
are involved. In spite of the seeming transparency of regulatory
authorities in publicly disclosing data and regulatory documents,
the exact methods used in their risk assessment procedures
remain convoluted and unclear. This was probably one of
the main reasons for a remarkable “flood” of commentaries
and editorial letters from different experts with strongly held
opinions, further fueling the controversy. This situation also
reflects the challenges in designing and implementing clinical
trials and appropriately interpreting large amounts of data.
In such instances, where substantial controversy exists in a
field, it is critical that original data from pivotal trials (such
as colloid 6S and CHEST) be made available for independent
(re-) analysis (145). Therefore, the reluctance of the authors
to share original data further exacerbated the debate (69).
Examining the available literature leaves the authors of this
review with the impression that HES safety and efficacy has
become a matter of opinion rather than evidence. Despite efforts
to apply evidence-based medicine, grounded guidelines for HES-
related clinical decision making are lacking. If and how the
2018 changes may impact the availability and use of HES in
veterinary medicine remains unclear. Moreover, if clinicians seek
alternatives to HES, the paucity of evidence for their safety
and efficacy in veterinary medicine should also be carefully
considered.
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